kstew call note focu top line miss
share vs et surpris stock reaction result today medtron
result mix sale came softer expect though ep beat believ market right frustrat compani
histori two step forward one step back said encourag commentari incom ceo geoff martha
make chang reduc volatil perform stick overweight rate find pipelin compel
believ bigger thesi chang
earn call manag acknowledg sale weak note larg transient issu upgrad erp
system custom buy pattern case ahead new product manag note occur late quarter
incom ceo geoff martha comment compani cant surpris like make chang discuss
chang compani go take june analyst day includ chang oper mechan certain intern metric
incent want convey assur take appropri action improv consist avoid futur
respect outlook manag remain upbeat outlook still expect see revenu acceler base
transient issu behind compani well contribut new product call manag note expect
acceler level organ sale guidanc exclud impact extra sell week
benefit year although martha mention initi compani would take improv
consist result would impact sale offset benefit extra sell week given quarter sale miss
fact geoff martha step ceo believ manag guidanc like somewhat conserv ensur
compani meets/beat forecast
 oo bloomberg im reach via im email call ith question
read first look first look anoth step forward one back quarter keep faith overweight
view compani ir present quarter click
report result revenu grow th light reflect seri larg transient issu new ever
off-set oper margin expans ell ahead expect result strong ep cash
flow grow th ahead plan
despit top-line short fall outlook impact unchang exclud impact coronaviru
revenu grew constant currenc organ revenu grow th fell short expect driven part custom
buy pattern ahead product launch cvg rtg mitg upgrad group erp system us canada result
temporari slow dow abil suppli custom hich case result lost procedur complet
process return full suppli abl off-set issu given mani emerg late quarter omar
ishrak note happi ith top line perform manag team focus resolv dynam
led result
drove signific oper leverag despit softer top line adjust oper margin expand see benefit
oper excel initi particularli sg line also strong financi leverag debt refinanc complet
earlier fiscal year adjust ep hich mid-point guidanc y/i
restor therapi group grew organ quarter rtg affect custom buy pattern bmp
continu slow dow slight share loss pain stim ahead dtm launch organ spine flat quarter reflect
draw dow infus inventori spine global us hen includ enabl technolog core spine
organ us brain therapi market quarter neurosurgeri low doubl digit grow th ith strong
grow th mazor outpac competit stealth station imag imag mida instrument neurovascular
anoth strong quarter ith mid-teen grow th driven grow th ischem stroke driven strong adopt
soltair stent retriev riptid aspir system react aspir cathet pain therapi market anoth sluggish
quarter slight share loss excit reaction ith dtm nan batteri arranti ith intelli
minim invas therapi grew organ includ flat result perform affect upgrad
erp system us canada case result loss procedur erp upgrad complet suppli slow dow
behind surgic innov driven advanc energi grew high singl digit grew driven low
doubl digit grow th gi solut busi high singl digit puls oximetri sensor
cardiac vascular group hich expect due part custom hold back purchas ahead
new product approv crhf saw high singl digit declin high pow er busi custom ere ait approv
cobalt/crom hich launch europ expect launch us heart failur although lvad
anniversari headw ind face past year busi declin low singl digit hasnt return grow th
rate expect tavr grew quarter market grow th rate us center perform tavr
fulli experienc field support littl tw o-third began aggress hire train new field personnel month
ago take longer becom product plan certifi addit personnel end fiscal year expect
improv rel market go forw ard ou tavr market share grew modestli pacemak busi grew high
singl digit market driven leadless pacemak micra av increas target popul
diabet grew slightli ahead expect us declin low doubl digit hich anticip result
competit challeng hile aw ait new product see strong enrol next tech pathw ay program current defer
portion revenu pump sale market ou hich repres half revenu solid mid-teen
grow th driven adopt
emerg market repres revenu grew china grew southeast asia eastern europ grew
includ russia south asia grew latin america grew
coronaviru activ respons team monitor viru manufactur oper manufactur slow ing
medic procedur rate expect neg impact impact difficult impact time
pipelin excit hat lie ahead us approv micra av pacemak launch underw ay us approv dcb av
fistula indic us approv launch stealth autoguid cranial robot system europ ce mark cobalt/crom
interstim micro percept db next quarter expect approv launch number addit new product
includ us approv cobalt/crom reveal linq icm interstim micro surescan mri lead percept db devic
expect european launch minim diamond ablat cathet minim intend file adult clinic data ith
fda march hich ould push expect approv beyond fiscal year-end pain unveil dtm spinal cord stim last
month train field forc novel ave form mitg make progress soft tissu robot program last
 eek announc acquisit digit surgeri
data releas ill use case attd later eek ith extrem condit ith advanc hybrid close loop algorithm
off-m renal denerv pivot trial data low risk bicuspid leaflet mobil risk stratif anti-infect
product june ada present us pivot data minim
sale organ ep came mid-point guidanc better fx better
adjust gross margin dow y/i due part increas china tariff off-set declin ith strong
oper leverag continu implement drive effici improv across compani hile time
make invest ahead upcom product launch
oper margin improv ex-fx
interest expens reduc due debt refin
adjust tax rate due increas stock comp deduct final tax return
billion ytd billion convers ell full year target plu remain commit
return minimum annual free cash flow sharehold
comfort ith current street forecast organ revenu grow th ep prior impact coronaviru
expect overal organ top line grow th approxim group expect cvg grow mitg grow
rtg approxim organ diabet flat dow low singl digit base recent currenc rate
expect neg impact
margin expect full year oper margin expand driven enterpris excel initi expect oper
margin slightli includ impact currenc flat constant currenc basi
expect interest expens
expect adjust tax rate around hich ould put annual rate hich low er expect reflect
benefit far year
rais full year guidanc rang reflect out-performance
expect adjust ep exclud impact coronaviru
exclud coronaviru still fluid difficult quantifi provid updat later quarter
geoff martha presid incom ceo
even though much transient perform level expect driver end quarter cant
surpris like compani make chang make chang ill discuss upcom investor
day june ill alk hat innovation-driven grow th mean comprehens set initi take
full advantag pipelin initi meant ensur compani see acceler revenu
pipelin improv predict one aspect manag plan address surpris saw quarter one issu
 eight revenu late quarter hich leav compani suscept surpris late quarter often
largest order come end month fix ill chang current oper mechan certain intern
metric incent ell ith extra eek come ill use good portion benefit launch
initi hen give guidanc ill guid underli benefit extra sell eek estim
sell eek net chang
better oper margin free cash flow outstand feel realli good oper rigor emerg market grow th
continu strong
slowdown see anyth ould caus compani concern see mid-teen
declin replac get better year next year see eak emea
product ere pend launch tyrx envelop report suppli issu
think close final plan ould think acceler grow th full year basi
guidanc impli full year
tavr world-wide growth first full quarter low risk happen quarter continu us
implant mid-teen market low head holiday take longer thought rep
surgic robot anyth bake updat hat talk januari
oper margin go continu look margin expans chang long rang guidanc
erp transit impact busi other impact across product line migrat
singl sap busi lost procedur dont think lost signific amount share
dcb trend us see improv dcb us
diabet encourag ith see de-risk pipelin particularli around sensor file ce mark put
us clinic data modul march review go ell meet ith fda later eek show full data set june
new product launch clear like micra av pretti clear dtm ill help mix
level confid interv ith new product recent launch interstim micro excit late spring launch
unit state percept launch europ diamond temp ce mark hich ill bigger impact
time crm/and interstim micro new product cobalt crome quarter linq quarter
interstim micro approv europ ell receiv excit ith product hen come us
coronaviru move part china global busi variabl get factori run
progress ell main variabl procedur run hubei provid shut dow that
china physician ask go help ith viru
spyral would timelin happen off-m pivot trial off-m on-m trial
efficaci endpoint avail year off-m ill modular submiss
think need on-m get final approv ill need get reimburs approv spyral approv europ
cvg expect low ere expect thing like lvad get micra av earli carri price uplift
tavr growth focu evolut new account ere spread field thin
econom impact work reduc volatil go take step back margin cash flow
improv ant make chang order come late quarter hich stress system manag ant
focu move busi come end quarter spread throughout quarter
gross margin recov back level one larger pressur increas china tariff
impact mix new product help
net expense/incom benefit driven sw ap defer comp program also sg
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli target pe calendar ep estim slight discount med-tech
compani trade grow th profil improv expect pe expand closer peer
risk may imped achiev barclay research valuat price nside risk includ fx rate
strengthen us dollar hich could pressur earn stock perform new product key futur success
compani thu extent compani unabl receiv fda approv could advers impact futur
outlook product includ compani surgic robot platform hich expect regulatori approv outsid unit
state begin key product includ micra av interstim micro minim futur iter continu blood
glucos monitor devic transcathet valv system upsid greater success ith new product margin expans
risk includ signific reimburs chang competit pressur product failur fda govern
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
